A detailed history of Cormorant Asset Management, LP transactions in Cabaletta Bio, Inc. stock. As of the latest transaction made, Cormorant Asset Management, LP holds 1,100,000 shares of CABA stock, worth $8.23 Million. This represents 1.08% of its overall portfolio holdings.

Number of Shares
1,100,000
Holding current value
$8.23 Million
% of portfolio
1.08%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

BUY
$16.79 - $25.38 $18.5 Million - $27.9 Million
1,100,000 New
1,100,000 $18.8 Million
Q3 2023

Nov 14, 2023

BUY
$11.84 - $18.65 $7.79 Million - $12.3 Million
657,685 Added 29.6%
2,879,424 $43.8 Million
Q2 2023

Aug 14, 2023

BUY
$7.65 - $13.95 $3.06 Million - $5.58 Million
400,000 Added 21.96%
2,221,739 $28.7 Million
Q1 2023

May 15, 2023

SELL
$7.08 - $12.62 $1.06 Million - $1.89 Million
-150,000 Reduced 7.61%
1,821,739 $15.1 Million
Q4 2022

Feb 14, 2023

BUY
$1.76 - $9.3 $1.44 Million - $7.6 Million
817,315 Added 70.8%
1,971,739 $18.2 Million
Q4 2021

Feb 14, 2022

SELL
$3.36 - $14.64 $1.54 Million - $6.69 Million
-457,199 Reduced 28.37%
1,154,424 $4.38 Million
Q2 2021

Aug 16, 2021

SELL
$7.2 - $11.73 $2.11 Million - $3.43 Million
-292,801 Reduced 15.37%
1,611,623 $13.9 Million
Q4 2020

Feb 16, 2021

SELL
$9.81 - $15.8 $1.6 Million - $2.57 Million
-162,878 Reduced 7.88%
1,904,424 $23.8 Million
Q3 2020

Nov 16, 2020

SELL
$9.71 - $14.41 $374,242 - $555,390
-38,542 Reduced 1.83%
2,067,302 $22.4 Million
Q2 2020

Aug 14, 2020

SELL
$6.39 - $11.28 $12 - $22
-2 Reduced -0.0%
2,105,844 $23.5 Million
Q1 2020

May 15, 2020

SELL
$6.0 - $18.67 $79,716 - $248,049
-13,286 Reduced 0.63%
2,105,846 $15.4 Million
Q4 2019

Feb 14, 2020

BUY
$7.88 - $17.71 $16.7 Million - $37.5 Million
2,119,132 New
2,119,132 $29.6 Million

Others Institutions Holding CABA

About Cabaletta Bio, Inc.


  • Ticker CABA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 29,014,000
  • Market Cap $217M
  • Description
  • Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor (CAAR) T cells that are designed to selectively bind and eliminate B cells, which produce di...
More about CABA
Track This Portfolio

Track Cormorant Asset Management, LP Portfolio

Follow Cormorant Asset Management, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cormorant Asset Management, LP, based on Form 13F filings with the SEC.

News

Stay updated on Cormorant Asset Management, LP with notifications on news.